What non‑benzodiazepine medication is appropriate for treating bruxism in an elderly patient?

Non-Benzodiazepine Medication for Bruxism in the Elderly

Tizanidine is the preferred non-benzodiazepine medication for elderly patients requiring pharmacotherapy for bruxism, initiated at the lowest available dose with gradual titration. 1

Rationale for Tizanidine as First-Line Agent

Tizanidine stands as the only muscle-relaxant specifically recommended by the American Geriatrics Society for older adults with musculoskeletal conditions, serving as a multipurpose adjuvant analgesic with a superior safety profile compared to traditional muscle relaxants. 1 This recommendation is particularly relevant for bruxism management, as the condition involves repetitive masticatory muscle activity that can benefit from muscle relaxation without the significant adverse effects associated with other agents. 2

Dosing Strategy

• Start at the lowest available dose and titrate gradually to minimize adverse effects such as dizziness and somnolence. 1
• Limit initial trial to 4–6 weeks maximum, with reassessment of therapeutic goals thereafter. 1

Alternative Non-Benzodiazepine Options with Evidence

Buspirone

Buspirone has demonstrated efficacy in controlling both awake and sleep bruxism in case series, with subjects reporting a mean 65% reduction in bruxism symptoms. 3 This anxiolytic agent may be particularly useful when anxiety is a contributing factor, as bruxism is increasingly recognized as a motor behavior influenced by psychological factors. 2

Trazodone

Trazodone showed robust response in treating awake bruxism in a patient with severe vascular dementia, with good tolerability and no untoward sedation. 4 This option may be considered when sleep disturbance coexists with bruxism, though evidence remains limited to case reports.

Propranolol

Beta-adrenergic blockade with propranolol successfully treated bruxism in two cases, particularly when coupled with neuroleptic-induced akathisia, suggesting involvement of adrenergic and serotonergic systems beyond dopaminergic pathways. 5 However, propranolol carries risk of moderate-to-severe xerostomia (7/16 participants in one study) and should be used cautiously in elderly patients with cardiovascular considerations. 6

Agents to Avoid in the Elderly

Traditional Muscle Relaxants

The American Geriatrics Society explicitly advises against cyclobenzaprine, methocarbamol, carisoprodol, chlorzoxazone, and metaxalone in elderly patients because they do not directly relax skeletal muscle, lack efficacy for chronic pain, and carry significant adverse-effect risks including anticholinergic burden and abuse potential. 1

Benzodiazepines

Benzodiazepines are strongly contraindicated during any recovery or rehabilitation period in elderly patients due to limited efficacy for pain conditions, no direct analgesic effect, and high risk of sedation, falls, and cognitive impairment that outweighs any potential benefit. 7, 1 This recommendation extends to bruxism management, where the risks clearly exceed benefits.

Baclofen

Baclofen should be considered only with extreme caution and when bruxism is refractory to other therapies, given limited data and higher adverse-effect risk in the elderly. 1 If prescribed, start at low doses and monitor for dizziness, somnolence, and gastrointestinal symptoms. 1 Critically, baclofen must be tapered slowly after prolonged use to avoid delirium and seizures. 1

Practical Prescribing Algorithm

Step 1 – Conservative Management First:

• Address behavioral factors, as bruxism is now defined as a motor behavior influenced by psychological and contextual factors. 2
• Consider mindfulness-based interventions, as higher dispositional mindfulness is associated with fewer and shorter contraction episodes in bruxism patients. 8
• Evaluate for anxiety, stress, and depression, which show stronger associations with bruxism and poorer sleep quality. 9

Step 2 – Pharmacotherapy Selection:

• First choice: Tizanidine at the lowest available dose. 1
• Alternative: Buspirone if anxiety is prominent. 3
• Consider: Trazodone if sleep disturbance coexists, particularly in dementia patients. 4

Step 3 – Initiation and Monitoring:

• Start with the lowest possible dose of the selected agent. 1
• Increase dose slowly in small increments, monitoring for adverse effects. 1
• Reassess after 4–6 weeks maximum. 1

Common Pitfalls to Avoid

• Do not prescribe traditional muscle relaxants under the assumption they relieve muscle spasm; their effects are nonspecific and not related to true muscle relaxation. 1
• Avoid polypharmacy: Muscle relaxants increase fall risk in the elderly, compounding existing vulnerabilities. 1
• Never use benzodiazepines for bruxism management in elderly patients due to deleterious effects on recovery, sedation, and fall risk. 7, 1
• Do not abruptly discontinue baclofen if it has been used; taper slowly to prevent withdrawal complications. 1

Evidence Limitations

A Cochrane systematic review found insufficient evidence on the effectiveness of pharmacotherapy for sleep bruxism, noting that most studies had small sample sizes (7-16 participants), cross-over designs, and imprecise results. 6 The review evaluated amitriptyline, bromocriptine, clonidine, propranolol, levodopa, and tryptophan against placebo, with results consistent with benefit, no difference, or harm across all agents. 6 This underscores the importance of using guideline-based recommendations for elderly patients, where tizanidine's safety profile makes it the preferred choice despite limited bruxism-specific evidence. 1